2025-04-11 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Review

**0) Numerical Overview & Initial Analysis:**

UNH's cumulative return significantly outperformed the S&P 500 (VOO) over the reviewed period.  While the exact timeframe isn't specified, the data shows a substantial difference.


**1) Performance Comparison with S&P 500:**

UnitedHealth Group Inc. (UNH) is a diversified healthcare company providing a range of health benefits and services.

* **UNH Cumulative Return:** 79.098%
* **VOO (S&P 500) Cumulative Return:** 65.782%
* **Return Difference:** 13.3%
* **Relative Divergence:** 57.3% (This indicates UNH's performance is in the upper 57.3rd percentile of its historical performance relative to the S&P 500 based on the provided min/max range.)

The alpha and beta analysis shows a generally positive alpha (outperformance relative to the market) across various periods, with notable variability in CAGR (Compound Annual Growth Rate) and MDD (Maximum Drawdown).  Beta values suggest varying levels of market sensitivity.  The significant increase in market capitalization (Cap(B)) indicates substantial growth.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 64.0% | 56.1% | 35.0% | 0.1 | 181.0 |
| 2016-2018  | 55.0% | 63.9% | 37.0% | 0.2 | 207.3 |
| 2017-2019  | 41.0% | 63.9% | 11.0% | 0.3 | 248.8 |
| 2018-2020  | -20.0% | 63.9% | -45.0% | 0.5 | 301.7 |
| 2019-2021  | 34.0% | 60.8% | -20.0% | 0.6 | 438.0 |
| 2020-2022  | 28.0% | 67.1% | 22.0% | 0.6 | 468.4 |
| 2021-2023  | 35.0% | 67.6% | 18.0% | 0.4 | 472.1 |
| 2022-2024  | -27.0% | 68.8% | -44.0% | 0.3 | 460.8 |
| 2023-2025  | 2.0% | 73.2% | -12.0% | 0.2 | 543.7 |


**2) Recent Price Movement:**

* **Closing Price:** $594.40
* **5-Day Moving Average:** $555.15
* **20-Day Moving Average:** $524.45
* **60-Day Moving Average:** $513.01

The price is significantly above all three moving averages, suggesting a recent upward trend.  The daily change of $2.75 represents a positive shift.


**3) Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4292 (Medium Risk)
* **RSI:** 81.76 (Overbought; suggests potential short-term correction)
* **PPO:** 1.40 (Positive; bullish signal)
* **Recent Relative Divergence:** +18.0 (Short-term upward momentum)
* **Expected Return (Long-term):** 10.6% (above S&P 500)

The high RSI value warrants caution, indicating the stock might be overbought in the short term.  The positive PPO and relative divergence support the upward trend. The significant price increase from the previous close suggests a possible short-term overbought scenario, potentially leading to a short-term correction, but the long-term outlook remains positive.


**4) Recent Earnings Analysis:**

| Date       | EPS    | Revenue         |
|------------|--------|-----------------|
| 2024-11-04 | 6.56   | $100.82 B       |
| 2024-08-09 | 4.58   | $98.86 B       |
| 2024-05-09 | -1.53  | $99.80 B       |
| 2023-11-06 | 6.31   | $92.36 B       |
| 2024-11-04 | 6.31   | $92.36 B       |

There's a duplicated entry in the data.  Revenue is consistently high, but EPS shows significant variability, including a negative EPS in Q2 2024.  Further investigation into the reasons behind the Q2 loss is needed.

**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $100.81B   | 21.14%        |
| 2024-09-30 | $100.82B   | 22.84%        |
| 2024-06-30 | $98.86B    | 22.31%        |
| 2024-03-31 | $99.80B    | 23.05%        |
| 2023-12-31 | $94.43B    | 23.30%        |

Revenue remains strong and relatively stable. Profit margins are consistently high but show some minor fluctuation.

**Capital and Profitability:**

| Quarter | Equity      | ROE    |
|---------|-------------|--------|
| 2024-12-31 | $92.66B    | 5.98%  |
| 2024-09-30 | $94.53B    | 6.41%  |
| 2024-06-30 | $89.36B    | 4.72%  |
| 2024-03-31 | $86.69B    | -1.63% |
| 2023-12-31 | $88.76B    | 6.15%  |

Equity shows some variability, and ROE mirrors the EPS fluctuations, with a significant negative value in Q1 2024.


**6) Overall Analysis:**

UNH has demonstrated strong historical performance, outperforming the S&P 500.  However, recent data reveals some volatility in EPS and ROE, requiring further investigation into the causes of the negative Q1 2024 figures. While the recent price action suggests strong short-term momentum, the high RSI indicates potential for a short-term correction.  Despite this, the long-term outlook, supported by generally positive alpha, strong revenue, and a high expected return, remains promising for long-term investors.  Thorough due diligence, including analysis of the Q2 2024 loss, is recommended before making any investment decisions.
